BMS 303141
CAY-16239-10 10 mg
Data Sheet: 
SDS:
SDS:
CAS
943962-47-8
Formulation
A crystalline solid
Purity
≥98%
MW
424,3
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.{27878} The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.{27877} Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.{27879} BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.{27876} At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.{27876}
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
